Atlas Trials

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Clinical trial NCT06299553 · RECRUITING

Trial details

NCT number
NCT06299553
Sponsor
Incyte Biosciences Italy S.r.l
Status
RECRUITING
Study type
OBSERVATIONAL
DLBCL - Diffuse Large B Cell Lymphoma
Start date
2023-12-04
Primary completion
2025-06-30
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.